NO20065861L - Metode for a stabilisere proteiner - Google Patents

Metode for a stabilisere proteiner

Info

Publication number
NO20065861L
NO20065861L NO20065861A NO20065861A NO20065861L NO 20065861 L NO20065861 L NO 20065861L NO 20065861 A NO20065861 A NO 20065861A NO 20065861 A NO20065861 A NO 20065861A NO 20065861 L NO20065861 L NO 20065861L
Authority
NO
Norway
Prior art keywords
bulk
monomeric protein
excipient
stabilizing proteins
agents
Prior art date
Application number
NO20065861A
Other languages
English (en)
Norwegian (no)
Inventor
Amer Jaber
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of NO20065861L publication Critical patent/NO20065861L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20065861A 2004-06-01 2006-12-19 Metode for a stabilisere proteiner NO20065861L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04076627 2004-06-01
PCT/EP2005/052413 WO2005117948A1 (en) 2004-06-01 2005-05-27 Method of stabilizing proteins

Publications (1)

Publication Number Publication Date
NO20065861L true NO20065861L (no) 2007-03-01

Family

ID=34928262

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065861A NO20065861L (no) 2004-06-01 2006-12-19 Metode for a stabilisere proteiner

Country Status (17)

Country Link
US (1) US7858082B2 (ru)
EP (1) EP1750750B1 (ru)
JP (1) JP2008500995A (ru)
CN (1) CN1993138B (ru)
AT (1) ATE543506T1 (ru)
AU (1) AU2005249232B2 (ru)
BR (1) BRPI0510527A (ru)
CA (1) CA2567309A1 (ru)
EA (1) EA012281B1 (ru)
ES (1) ES2381674T3 (ru)
HK (1) HK1102561A1 (ru)
IL (1) IL179617A0 (ru)
MX (1) MXPA06014079A (ru)
NO (1) NO20065861L (ru)
UA (1) UA93349C2 (ru)
WO (1) WO2005117948A1 (ru)
ZA (1) ZA200610041B (ru)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
MXPA06001283A (es) 2003-08-05 2006-04-11 Novo Nordisk As Derivados de insulina novedosos.
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
WO2007074133A2 (en) 2005-12-28 2007-07-05 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
NZ571757A (en) * 2006-04-21 2012-01-12 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
NZ573360A (en) 2006-05-04 2012-08-31 Boehringer Ingelheim Int Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
ES2744384T3 (es) 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
WO2009027334A1 (en) * 2007-08-24 2009-03-05 Novo Nordisk A/S Reduction of dimer content in factor vii polypeptide compositions by heat treatment
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
RS52417B (en) * 2007-12-20 2013-02-28 Merck Serono S.A. PEG-INTERFERON-BETA FORMULATIONS
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
WO2010045168A1 (en) 2008-10-16 2010-04-22 Andrew Desbarats Method and apparatus for producing alcohol or sugar using a commercial-scale bioreactor
KR101939557B1 (ko) 2008-10-17 2019-01-17 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 ｇｌｐ－1 효능제의 병용물
AU2009309623B9 (en) 2008-10-30 2014-10-02 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
WO2010057259A1 (en) * 2008-11-19 2010-05-27 James Cook University Protein stability assay using a fluorescent reporter of protein folding
TWI508965B (zh) 2008-12-23 2015-11-21 Boehringer Ingelheim Int 有機化合物的鹽形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
CN107308442B (zh) 2009-11-13 2022-10-18 赛诺菲-安万特德国有限公司 包含glp-1激动剂、胰岛素和甲硫氨酸的药物组合物
PT3345593T (pt) * 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
JP2013512229A (ja) 2009-11-27 2013-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子型が同定された糖尿病患者のリナグリプチン等のｄｄｐ−ｉｖ阻害薬による治療
NZ602921A (en) 2010-05-05 2016-01-29 Boehringer Ingelheim Int Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
MX2012014247A (es) 2010-06-24 2013-01-18 Boehringer Ingelheim Int Terapia para la diabetes.
LT2611458T (lt) 2010-08-30 2016-12-27 Sanofi-Aventis Deutschland Gmbh Ave0010 panaudojimas gaminant vaistą, skirtą 2 tipo cukrinio diabeto gydymui
CN103816115B (zh) * 2010-08-31 2017-06-27 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
ME02506B (me) 2010-11-11 2017-02-20 Abbvie Biotechnology Ltd VISOKA KONCETRACIJA TEČNIH FORMULACIJA ANTI TNF alfa ANTITIJELA
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
MX370264B (es) 2011-08-29 2019-12-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN103271871A (zh) * 2013-03-18 2013-09-04 长春海伯尔生物技术有限责任公司 一种重组人干扰素注射液及其制备方法
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
SI3229828T1 (sl) 2014-12-12 2023-06-30 Sanofi-Aventis Deutschland Gmbh Formulacija s fiksnim razmerjem inzulin glargin/liksisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
EP3468562A1 (en) 2016-06-10 2019-04-17 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
AR109621A1 (es) * 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
CA3081094A1 (en) * 2017-11-20 2019-05-23 Alison J. GILLESPIE Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4432895A (en) * 1982-11-24 1984-02-21 Hoffmann-La Roche Inc. Monomeric interferons
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4879111A (en) 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
JP4878664B2 (ja) * 1996-12-24 2012-02-15 バイオジェン・アイデック・エムエイ・インコーポレイテッド 安定な液体インターフェロン処方物
US6013253A (en) 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
CA2304808C (en) * 1997-09-23 2011-03-22 Michael Tschope Liquid interferon-.beta. formulations
ES2224649T3 (es) 1998-04-28 2005-03-01 Applied Research Systems Ars Holding N.V. Conjugados de poliol-ifn-beta.
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
CN1522159A (zh) * 2001-06-29 2004-08-18 马克西根公司 干扰素配制品
JP5057648B2 (ja) * 2002-09-26 2012-10-24 塩野義製薬株式会社 安定化されたタンパク組成物
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations

Also Published As

Publication number Publication date
AU2005249232B2 (en) 2010-08-05
IL179617A0 (en) 2007-05-15
US7858082B2 (en) 2010-12-28
JP2008500995A (ja) 2008-01-17
BRPI0510527A (pt) 2007-10-30
MXPA06014079A (es) 2007-02-15
EA012281B1 (ru) 2009-08-28
CA2567309A1 (en) 2005-12-15
ATE543506T1 (de) 2012-02-15
EP1750750A1 (en) 2007-02-14
CN1993138B (zh) 2010-12-15
ZA200610041B (en) 2008-07-30
CN1993138A (zh) 2007-07-04
ES2381674T3 (es) 2012-05-30
AU2005249232A1 (en) 2005-12-15
US20070244299A1 (en) 2007-10-18
HK1102561A1 (en) 2007-11-30
EP1750750B1 (en) 2012-02-01
UA93349C2 (ru) 2011-02-10
EA200602254A1 (ru) 2007-06-29
WO2005117948A1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
NO20065861L (no) Metode for a stabilisere proteiner
NO2017027I2 (no) efmoroctocog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
EA200602257A1 (ru) Стабилизированные жидкие препаративные формы интерферона
WO2005021592A3 (en) Enhancing the circulating half-life of interleukin-2 proteins
DE60144145D1 (de) Subtilisin-variante
EA201892671A1 (ru) Пегилированный свиной интерферон и способы его применения
EP1496926A4 (en) USE OF TRANSTHYRETIN PEPTIDE / PROTEIN FUSIONS FOR INCREASING THE SERUM HALF-LIFE OF PHARMACOLOGICALLY ACTIVE PEPTIDES / PROTEINS
NZ591415A (en) Haemophilus influenzae type B
EA200800327A1 (ru) Стабилизированные жидкие композиции интерферона, не содержащие человеческий сыворотный альбумин
PT1118619E (pt) Metodo para identificar agentes activos contra o vhc utilizando as coordenadas estruturais da protease do virus da hepatite c
ECSP066495A (es) Composiciones y metodos para inhibir la infección por virus de síndrome de punto blanco (wssv)
DE60328469D1 (de) Aminosäuren mit affinität zu alpha-2-delta-protein
IS8308A (is) Amínósýrur með sækni fyrir a2o prótíninu
DK1349944T3 (da) Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latens
DK1276763T3 (da) Anti-fryseproteiner, deres fremstilling og anvendelse
FR2857267B1 (fr) Formulation stabilisante et solubilisante pour les proteines cryoprecipitables.
HUP0401732A2 (hu) Kopolimerek használata aktív szerként peptidet és fehérjét tartalmazó galenikus formák előállításához
ATE464320T1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
DK1350838T3 (da) Ekspression af rekombinante humane proteiner i tetrahymena
WO2008068428A3 (fr) Utilisation cosmétique de protéines de type chitinase
DE60015559D1 (de) Sentrin-spezifische menschliche protease senp1
ATE506433T1 (de) Prozessierung von peptiden und proteinen
ATE468753T1 (de) Molkenproteinhydrolysate
FR2862660B1 (fr) Systeme d'expression inductible de proteines recombinantes chez les cyanobacteries.
ATE392480T1 (de) Verfahren zur vorhersage der expressionseffizienz in zellfreien expressionssystemen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application